Ignite Creation Date:
2024-05-05 @ 11:25 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00036296
Status:
COMPLETED
Last Update Posted:
2011-04-13
First Post:
2002-05-08
Brief Title:
Effects of Talampanel on Patients With Advanced Parkinsons Disease
Sponsor:
Teva Branded Pharmaceutical Products RD Inc
Organization:
Teva Branded Pharmaceutical Products RD Inc
Study Overview
Official Title:
Effects of Talampanel on Patients With Advanced Parkinsons Disease Who Have Been on Sinemet for More Than 5 Years and Have Dyskinesia Abnormal Involuntary Movements
Status:
COMPLETED
Status Verified Date:
2009-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to test the safety and effectiveness of the study drug Talampanel when used to treat patients with involuntary movements known as dyskinesias as a result of treatment to Parkinsons disease
It is not clear why people with Parkinsons disease develop involuntary movements dyskinesias but studies show that blocking receptors in the brain for a chemical called glutamate decreases these movements Talampanel is a drug which blocks these receptors
It is not clear why people with Parkinsons disease develop involuntary movements dyskinesias but studies show that blocking receptors in the brain for a chemical called glutamate decreases these movements Talampanel is a drug which blocks these receptors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None